{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:50:41Z","timestamp":1767707441457,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ajoc.2023.101933","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T02:25:33Z","timestamp":1696559133000},"page":"101933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-4410","authenticated-orcid":false,"given":"Jared A.","family":"Moon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-5552","authenticated-orcid":false,"given":"Eileen C.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe H.","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ajoc.2023.101933_bib1","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1007\/s12032-010-9719-5","article-title":"Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma","volume":"28","author":"Yoong","year":"2011","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.ajoc.2023.101933_bib2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/10428194.2022.2045599","article-title":"Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"63","author":"Haddad","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.ajoc.2023.101933_bib3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1080\/10428194.2022.2056180","article-title":"Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients","volume":"63","author":"Lipton","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.ajoc.2023.101933_bib4","doi-asserted-by":"crossref","first-page":"NP56","DOI":"10.1177\/11206721221078675","article-title":"Bilateral optic disc edema as a possible complication of cabozantinib use-a case report","volume":"33","author":"Huang","year":"2023","journal-title":"Eur J Ophthalmol"},{"year":"2012","series-title":"Iclusig \u00ae (Ponatinib Hydrochloride) Tablets Prescribing Information","key":"10.1016\/j.ajoc.2023.101933_bib5"},{"year":"2013","series-title":"Ariad Hammered on Toxicity Concerns for Leukemia Drug Iclusig","author":"Carroll","key":"10.1016\/j.ajoc.2023.101933_bib6"},{"year":"2013","series-title":"After Brief Halt, F.D.A. Allows Sales of Drug for Cancer to Resume","author":"Pollack","key":"10.1016\/j.ajoc.2023.101933_bib7"},{"issue":"21","key":"10.1016\/j.ajoc.2023.101933_bib8","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ajoc.2023.101933_bib9","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101933_bib10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1080\/09273948.2020.1866618","article-title":"Ponatinib inducing a panuveitis with choroidal effusions and neurosensory retinal detachment in a patient with chronic myeloid leukaemia","volume":"30","author":"Patil","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101933_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/eye.2017.222","article-title":"Neuro-ophthalmic side effects of molecularly targeted cancer drugs","volume":"32","author":"Bhatti","year":"2018","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ajoc.2023.101933_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10384-008-0561-7","article-title":"Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)","volume":"52","author":"Kwon","year":"2008","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajoc.2023.101933_bib13","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/OPX.0b013e318269111d","article-title":"Imatinib mesylate (Gleevec) induced unilateral optic disc edema","volume":"89","author":"DeLuca","year":"2012","journal-title":"Optom Vis Sci"},{"issue":"6","key":"10.1016\/j.ajoc.2023.101933_bib14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2403364","article-title":"Visual disturbance due to retinal edema as a complication of imatinib","volume":"18","author":"Kusumi","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101933_bib15","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jcjo.2021.06.022","article-title":"Papilledema and intracranial hypertension in leukemia: case series and review","volume":"57","author":"Mejia-Vergara","year":"2022","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2023.101933_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10792-007-9038-9","article-title":"Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia","volume":"27","author":"Govind Babu","year":"2007","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajoc.2023.101933_bib17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.survophthal.2021.11.007","article-title":"A review of etiology, pathophysiology, diagnosis, and management","volume":"67","author":"Xie","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajoc.2023.101933_bib18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","article-title":"Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children","volume":"81","author":"Friedman","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101933_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245199362300141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245199362300141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:01:19Z","timestamp":1762527679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245199362300141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"alternative-id":["S245199362300141X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101933","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101933"}}